17 June 2021 - Ordinarily, the approval of a new drug for a dreaded disease affecting millions of Americans would be a cause for celebration.
But aducanumab, which the FDA approved last week to treat Alzheimer’s disease, is no ordinary drug.
It encapsulates everything that ails the regulation of the pharmaceutical industry and is a grim reminder of the soul-searching about the FDA’s integrity that’s desperately needed.